Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CKS1B | P61024 | 1/20 | 0.36 |
| ▸ | SKP1 | P63208 | 1/20 | 0.36 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 7/20 | 0.35 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14801759 | 1.00 | CKS1B (0.36) | CKS1BSKP1SKP2RETEIF2AK4 | |
| SCHEMBL14801429 | 0.90 | CKS1B (0.37) | CKS1BSKP1SKP2RETEIF2AK4 | |
| SCHEMBL14801330 | 0.88 | RET (0.42) | CKS1BSKP1SKP2RETEIF2AK4 | |
| SCHEMBL14801235 | 0.88 | RET (0.42) | CKS1BSKP1SKP2RETEIF2AK4 | |
| SCHEMBL14803013 | 0.88 | RET (0.42) | CKS1BSKP1SKP2RETEIF2AK4 | |
| SCHEMBL14803018 | 0.88 | CKS1B (0.38) | CKS1BSKP1SKP2RETJAK3 | |
| SCHEMBL14801233 | 0.88 | RET (0.42) | CKS1BSKP1SKP2RETEIF2AK4 | |
| SCHEMBL14800678 | 0.88 | CKS1B (0.38) | CKS1BSKP1SKP2RETJAK3 | |
| SCHEMBL14801123 | 0.80 | DPP4 (0.38) | JAK3BTKMAP4K4SSTR4DPP4 | |
| SCHEMBL14801458 | 0.79 | EIF2AK4 (0.40) | CKS1BSKP1SKP2RETEIF2AK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9505746-B2 | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | GENENTECH, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| EP-2760857-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | F.HOFFMANN-LA ROCHE AG (CH) | 2014-08-06 | — | — | EP | disclosed |
| US-20140080801-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-8614206-B2 | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2013-12-24 | — | — | US | disclosed |
| WO-2013045461-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-04-04 | — | — | WO | disclosed |
| US-20130079321-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079321-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | PIM1, PIM2, PIM3 | CKS1B 165/4885SKP1 579/4885SKP2 430/4885 |
| US-20140080801-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | PIM1, PIM2, PIM3 | CKS1B 165/4885SKP1 579/4885SKP2 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.